According
to Market Research Future, Urethritis Market is segmented By Type (Infective
Urethritis (Non-Gonococcal, Gonococcal), Nonspecific Urethritis), By Diagnosis
(Microbial Culture Tests), Drug Treatment (Pain Killers, Anti-Bacterial,
Antivirals), By End.
Urethritis is an inflammation of the
urethra, or the tube that carries urine. It shows various symptoms such as pain
while urinating and an increased urge to urinate. Additionally, burning
sensation while urinating, presence of blood in the semen or urine, frequent
urge and discomfort while urinating, abnormal discharge from the vagina or
penis, etc. are other common symptoms. Other serious manifestation of
urethritis include damage to the reproductive system, pelvic inflammatory
disease (PID), which can result in infertility, and others. The primary cause
of urethritis is usually infection by bacteria, while viral infection for
pre-existing sexually transmitted diseases being the secondary cause.
Urethritis is also caused by mechanical or chemical damage to the urethra
during treatment or catheterization. Urethritis should not be confused with
urinary tract infection (UTI). Urethritis is an inflammation of the urethra,
while a UTI is an infection of the urinary tract and both may have similar
symptoms, but often require different treatment.
Urethritis
Market is expected to reach USD 18.0 billion by 2023 at a CAGR of ~ 8.0 %
during the forecast period 2019-2023.
Females have a greater chance of developing
urethritis than males because of the nearness of urethra to the anus, which
increases the chance of microbial infection. Also men’s urethras is much longer
than women’s. According to the Centers for Disease Control and Prevention
(CDC), causative organisms associated with urethritis include Neisseria
gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Human papillomavirus
(HPV), Herpes simplex virus (HSV), and Cytomegalovirus (CMV) and others.
According to Antimicrobe, Nongonococcal bacteria caused urethritis in
approximately 4 million Americans in 2015 accounting for 80% of the cases.
According to Department of Health, U.K., urethritis accounts for 0.005% of
hospital consulting with a high 97% of hospital consulting for urethritis
requiring hospital admission. Almost 20% of hospital admissions for urethritis
requires an emergency.
Rising demand for the treatment due to
growing population, increasing screening, rising number of geriatrics, rising
safety and success of drug treatment, the extricating nature of the pain, and
others are driving the growth of the market. However, complications of
treatment such as side effects, emergence of bacterial resistance to
antibiotics, cost of urethritis treatment, and others may hamper the market
growth.
Key Players in the Global Urethritis
Market
·
F. Hoffmann-La Roche AG,
·
GlaxoSmithKline,
·
AbbVie,
·
Johnson & Johnson, and Merck &
Co.,
·
Eli Lilly and Company,
·
Bristol-Myers Squibb Company,
·
Bayer AG,
·
AstraZeneca plc. and others.
Segments
The global urethritis market has been
segmented on the basis of types, diagnosis, drug treatment, and end user.
Based on the types, the market has been
segmented as infective urethritis and nonspecific urethritis.
Based on the diagnosis, the market has
been segmented as physical examination, microbial culture tests, and others.
Based on the drug treatment, the market
has been segmented as pain killers, anti-bacterials, antivirals, and others.
Based on the end user, the market has
been segmented as hospitals and clinics, research and academics, and others.
Global Urethritis Market Regional
Analysis
The Americas accounts for a significant
market share owing to high expenditure on the health care, especially, of the
U.S. and Canada. Additionally, the greater number of hospitalization procedures
due to greater healthcare penetration in the U.S. and Canada drives the
urethritis market. The high concentration of the major hospitals in the
developed countries of this region coupled with good reimbursement rates are
adding fuel to the market growth. The consolidation of large healthcare players
in the U.S. also leads the growth of the market due to increased buying
power of the healthcare players.
Asia Pacific region is expected to grow
rapidly; China and India are likely to lead this market due to the fast growing
healthcare sector and large unmet needs over the forecast period. South East
Asian countries such as China, India, and Malaysia are projected to contribute
highly to the market growth. The growing penetration of healthcare industry in
the Asia Pacific region is expected to drive the future urethritis market in
the region.
Europe is the second largest market in
the world due to growing healthcare industry and healthcare penetration. The
European market growth is led by countries such as Germany and France. Germany
is expected to be the fastest growing market over the assessment period due to
the large pharmaceutical industry.
Gulf nations such as Saudi Arabia and the
UAE are estimated to drive the Middle East & African market. Other Middle
East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African
region is expected to witness a poor growth owing to poor economic and
political conditions, and poor healthcare development. Other regions are
expected to be laggards due to poor social development and tribal identities
such as sub Saharan Africa.
Browse More Pharmaceutical
Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report
No comments:
Post a Comment